Screener
Kiniksa Pharmaceuticals International, plc KNSA Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 2,575 | 1,943 |
| Operating lease right-of-use assets | 8,353 | 9,807 |
| Other long-term assets | 10,834 | 11,307 |
| Intangible asset, net | 14,750 | 15,250 |
| Deferred tax assets | 190,965 | 198,149 |
| Total assets | $896,110 | $763,633 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's intangibles (net)?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported intangibles (net) of $14.75M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's intangibles (net) changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's intangibles (net) decreased by 6.3% year-over-year, from $15.75M to $14.75M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Kiniksa Pharmaceuticals International, plc's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude